By Menopause Reviewed Editorial Team | Last reviewed: May 2026
Walk through any functional medicine practice, longevity clinic, or wellness-forward social media feed in 2025 or 2026, and you will encounter peptide therapy promoted for virtually every perimenopausal complaint: weight gain, fatigue, brain fog, low libido, poor sleep, joint pain, declining muscle mass, and immune dysregulation. Influencers and telehealth platforms offer stacks of multiple peptides simultaneously. Price points run from hundreds to thousands of dollars per month.
The wellness industry's ability to outrun the research by several years is not new. But with peptides, the gap between marketing claims and peer-reviewed evidence is particularly wide, and the risks introduced by unregulated sourcing are underappreciated by many of the women purchasing them. This article examines the specific peptides most frequently promoted for midlife women, what the clinical literature actually shows for each, and what women should understand before making an informed decision.
What Peptides Are
Peptides are short chains of amino acids, linked by peptide bonds. Proteins are also amino acid chains, but by convention the term "peptide" generally refers to molecules of fewer than 50 amino acids. The body produces thousands of endogenous peptides that act as hormones, neurotransmitters, and signaling molecules, including insulin, oxytocin, and glucagon.
The clinical and commercial interest in exogenous peptides rests on the idea that introducing specific peptide sequences can trigger targeted biological responses, stimulating growth hormone release, accelerating tissue repair, modulating immune function, or activating specific receptor pathways. Some of this is well-established biology. The FDA has approved multiple peptide drugs, including insulin analogs, semaglutide (Ozempic/Wegovy), and liraglutide, which are synthetic GLP-1 receptor agonists; sermorelin and tesamorelin, which stimulate growth hormone release; and bremelanotide (Vyleesi), a melanocortin receptor agonist approved for hypoactive sexual desire disorder.
The vast majority of peptides sold in the wellness market, however, are not FDA-approved drugs. They are sold as "research chemicals" for purported non-human use, a regulatory loophole that allows manufacturers to sell substances for which there are no clinical trials, no manufacturing oversight, and no guarantee of purity or potency. This distinction between FDA-approved peptide drugs and research-use peptides is the most important context for evaluating any claim made about peptide therapy for menopause.
The Peptides Being Marketed to Midlife Women
CJC-1295 and Ipamorelin (Growth Hormone Secretagogues)
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a synthetic growth hormone secretagogue that acts on ghrelin receptors. They are frequently combined to produce synergistic growth hormone (GH) and insulin-like growth factor 1 (IGF-1) stimulation. The marketing rationale for midlife women centers on age-related GH decline, with claims that restoring GH levels will improve body composition, reduce visceral fat, improve sleep quality, and increase energy.
A 2006 study in The Journal of Clinical Endocrinology and Metabolism demonstrated that subcutaneous CJC-1295 produced dose-dependent sustained increases in GH and IGF-1 in healthy adults, with an acceptable short-term tolerability profile. Ipamorelin was characterized in animal models and in vitro studies in the late 1990s and early 2000s, showing selective GH release without significant cortisol or prolactin stimulation.
What the evidence does not show is any clinical trial in perimenopausal or postmenopausal women demonstrating that CJC-1295/Ipamorelin combination improves the outcomes marketed: weight management, cognitive function, or sleep quality in this specific population. The existing human data are from healthy young adults and small trials in GH-deficient populations. GH stimulation is not without risk: elevated IGF-1 is associated with increased cell proliferation, and concerns about cancer risk with chronic supraphysiologic GH or IGF-1 elevation are legitimate, particularly in women with a history of hormone-sensitive cancers.
BPC-157 (Body Protection Compound)
BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a human gastric protein. Its proposed mechanisms include promotion of angiogenesis, modulation of nitric oxide signaling, neuroprotective effects, and acceleration of tissue healing in tendons, ligaments, and gut mucosa. The marketing to midlife women typically emphasizes joint health, gut inflammation, and recovery.
The honest summary of the evidence is that it is preclinical. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine found that as of that date, only three published human studies had examined BPC-157: a small retrospective study of intraarticular knee injections, a pilot study of intravesicular injections for interstitial cystitis, and a pharmacokinetics/safety study in two healthy adults receiving intravenous infusions. All three studies had significant methodological limitations, and none were randomized controlled trials.
The animal model evidence for BPC-157 is extensive and generally positive across multiple organ systems. But animal-to-human translation in musculoskeletal biology is historically poor, and the absence of human trial data means that safety and efficacy profiles in women, particularly over extended use, are unknown. There are also preclinical signals suggesting potential for promoting angiogenesis in tumor models, which have not been adequately evaluated in humans.
BPC-157 is not FDA-approved for any indication. It was placed on the FDA's list of bulk drug substances that may not be used in compounding (Category 2) in proposed rulemaking, based on concerns about its lack of clinical evidence and unknown risk profile.
Tesamorelin (Off-Label Use)
Tesamorelin is an FDA-approved GHRH analog, sold as Egrifta, indicated specifically for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. This is a narrow, well-studied indication. The FDA approval is based on randomized clinical trial data in HIV-positive populations with documented lipodystrophy as a consequence of antiretroviral therapy.
Off-label tesamorelin is being marketed to midlife women as a treatment for menopausal visceral fat accumulation. This application has not been studied in clinical trials. Visceral fat redistribution during menopause is real and well-documented, driven by declining estrogen. But using a drug validated in one condition (HIV lipodystrophy) as a proxy for another condition (menopausal body composition change) is not appropriate extrapolation, particularly when the hormonal context, the mechanisms of fat redistribution, and the risks are different.
Tesamorelin is available by prescription only. It is not a research peptide. Its off-label use should be discussed explicitly with a physician who can evaluate individual cardiovascular and cancer risk factors.
PT-141 / Bremelanotide (Vyleesi)
This is the one FDA-approved peptide directly relevant to a common menopausal complaint.
Bremelanotide (brand name Vyleesi) is a melanocortin receptor agonist approved by the FDA in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The phase 3 RECONNECT trials, published in Obstetrics and Gynecology in 2019, demonstrated statistically significant improvements in sexual desire scores and reductions in distress related to low sexual desire compared with placebo.
There are several important caveats. First, the FDA approval is specifically for premenopausal women; evidence in postmenopausal women is limited. Second, the most common adverse effect, nausea, occurred in approximately 40 percent of participants, leading to high discontinuation rates in the trials. Third, bremelanotide is administered as a subcutaneous self-injection 45 minutes before anticipated sexual activity, not as a daily medication. Fourth, it is approved for HSDD, a clinical diagnosis requiring that the low desire be distressing to the woman and not explained by a medical condition, medication, or relationship factor.
The research-grade PT-141 sold online is not the same product as FDA-approved Vyleesi, and purchasing it through informal channels introduces purity and dosing risks described below.
Thymosin Alpha-1
Thymosin alpha-1 is an immunomodulatory peptide being marketed for immune support and longevity. A pharmaceutical version, Zadaxin (thymalfasin), is approved in some countries outside the United States for hepatitis B, hepatitis C, and as an adjuvant in cancer treatment. In the US, it is not FDA-approved for any indication and is sold as a research compound.
The immune-boosting claims being made for general wellness use in midlife women are not supported by clinical trial data in that population. The existing evidence is largely in immunocompromised patients with specific infections or cancer, where results have been mixed. Extrapolation to healthy women seeking general immune support is not evidence-based.
What the Peer-Reviewed Evidence Actually Shows
A pattern runs through the above: compelling preclinical biology, limited or absent human trials, and near-zero perimenopause-specific research.
This is not a condemnation of all peptide research. The GLP-1 receptor agonists began as peptides studied in animal models before becoming some of the most important drugs in contemporary medicine. BPC-157 may eventually demonstrate genuine clinical utility once it clears the human trial threshold. The problem is the sequence: rigorous clinical testing should precede widespread public use, not follow it.
For midlife women specifically, the evidence base is stark. A systematic search of PubMed for randomized controlled trials examining peptide therapies (excluding FDA-approved GLP-1 agonists) for perimenopause or menopause-related symptoms returns no relevant results as of early 2026. The perimenopausal body composition changes, sleep disruption, libido decline, joint pain, and immune changes that peptides are marketed to address are real and clinically significant. They also have treatments with actual evidence: hormone therapy, physical conditioning, cognitive behavioral therapy, SSRIs and SNRIs, and for libido specifically, FDA-approved options including bremelanotide (for premenopausal HSDD) and ospemifene or vaginal estrogen for dyspareunia.
The Big Problem: Purity, Batch Testing, and Counterfeit Risk
Setting aside efficacy questions, purity is a concrete safety issue with unregulated peptide products.
Peptides marketed as research chemicals are not manufactured under FDA Good Manufacturing Practice (GMP) regulations. There is no requirement to verify identity, potency, or sterility before sale. Independent third-party testing has found that peptide products sold online frequently contain the wrong compound, the labeled compound at the wrong concentration, bacterial endotoxins that cause inflammatory reactions, or degradation products from improper storage.
A Certificate of Analysis (COA) is a document produced by a laboratory analyzing a specific batch of a compound, verifying its identity and purity using methods such as high-performance liquid chromatography (HPLC) or mass spectrometry. A legitimate COA names the specific batch tested, the testing laboratory, the method used, and the result. Many peptide vendors display COAs that are outdated, fabricated, or produced by internal testing rather than independent third parties.
Independent analytical laboratories such as Janoshik Analytical provide third-party testing that is publicly searchable. Vendor claims should be verifiable against independently published data.
Related Resource: If You Are Researching Peptide Providers
The lack of regulatory oversight in the peptide market means that source quality varies dramatically. If you are researching peptide providers, look for ones that publish third-party Certificates of Analysis from independent laboratories. PeptidesRated maintains a free, independent database of 50+ providers with batch-level purity data, allowing you to verify third-party test results before purchasing. This kind of due diligence is the minimum standard for anyone considering research compounds.
What We Would Recommend Reading First
Before spending significant money or taking on the risks of unregulated compounds, the following represents a more evidence-grounded starting point for the symptoms commonly driving interest in peptide therapy.
For body composition and metabolic changes. Menopausal weight redistribution is primarily addressed through sustained resistance training, which preserves lean mass and attenuates visceral fat accumulation, and dietary pattern (adequate protein is consistently under-consumed in midlife women). If obesity-related metabolic risk is significant, FDA-approved GLP-1 receptor agonists (semaglutide, liraglutide) have robust clinical trial data and are appropriate to discuss with a physician.
For low libido. Genitourinary syndrome of menopause, which causes pain with intercourse and thereby reduces desire, responds to vaginal estrogen, ospemifene, and non-hormonal lubricants. Systemic HRT addresses libido through multiple pathways including improved sleep and vasomotor symptom relief. For HSDD specifically in premenopausal women, bremelanotide (Vyleesi) is FDA-approved. Off-label flibanserin (Addyi) is an option some clinicians use.
For joint pain. The evidence for physical therapy, resistance training, and anti-inflammatory dietary patterns in perimenopausal musculoskeletal symptoms is more solid than for any peptide. If HRT is appropriate, estrogen's anti-inflammatory effects on synovial tissue may also offer benefit.
For immune support. No supplement or peptide has demonstrated reliable immune-boosting effects in healthy, well-nourished adults. Established immune-relevant lifestyle factors include consistent sleep, moderate exercise, and vaccination.
The peptide biology is genuinely interesting, and the field may mature into useful therapies over the next decade. But for women navigating perimenopause today, the evidence base for peptide therapy as a primary or supplement strategy for hormonal symptoms remains too thin to justify the cost and risk.
Sources
- Bhasin S, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Regeneration or risk? A narrative review of BPC-157 for musculoskeletal applications. Current Reviews in Musculoskeletal Medicine. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
- Kaminetsky J, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstetrics and Gynecology. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/
- FDA approves tesamorelin for HIV-related lipodystrophy. Annals of Pharmacotherapy. 2010. https://pubmed.ncbi.nlm.nih.gov/21115997/
- Mayo Clinic: Bremelanotide (subcutaneous route). https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022. https://pubmed.ncbi.nlm.nih.gov/35797481/
- Endocrine Society Scientific Statement: Compounded Bioidentical Hormones. 2019. https://www.endocrine.org/advancing-research/scientific-statements/health-policy/compounded-bioidentical-hormones-in-endocrinology-practice
- BPC-157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07437547
- Janoshik Analytical: Independent third-party peptide testing. https://janoshik.com